Leadership | Appendix B: Panel Roster and Financial Disclosures | Adult and Adolescent Opportunistic Infection | ClinicalInfo

Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV

The information in the brief version is excerpted directly from the full-text guidelines. The brief version is a compilation of the tables and boxed recommendations.

Updated

May. 14, 2019

Reviewed

May. 14, 2019

Appendix B: Panel Roster and Financial Disclosures

Leadership

Leadership
Member		Financial Disclosure
Member		Company	Relationship
Benson, Constance	University of California, San Diego	Dr. Benson has served on an advisory and a data monitoring board for GlaxoSmithKline/ViiV Healthcare and received research grants awarded to her institution from Gilead Sciences, Inc. Her spouse has served as a consultant to CytoDyn, Gilead Sciences, Inc, Pfizer, and Vir Biotechnology; has received grant support from Gilead Sciences, Inc; and holds stock or stock options in Antiva Biosciences and CytoDyn.
Brooks, John T.	Centers for Disease Control and Prevention	None	N/A
Holmes, King	University of Washington School of Medicine	Merck	Honoraria
Masur, Henry	National Institutes of Health	None	N/A
Pau, Alice	National Institutes of Health	None	N/A
Note: Members were asked to disclose all relationships from 24 months prior to the updated date. The period of reporting was from May 1, 2017, through May 1, 2019.

Download Guidelines

Section OnlyPDF (337.79 KB)
Full GuidelinePDF (3.78 MB)
Tables OnlyPDF (481.21 KB)